Taking the HIV drug Isentress once a day is not as effective as the standard twice-daily regimen, reported drug manufacturer Merck & Co. Based on these initial results, Merck is suspending the Phase III trial of once-daily dosing.
Isentress is the only HIV drug that works by blocking integrase, an enzyme that allows HIV to insert its genetic material into human DNA. Taken twice a day, Isentress is used among both previously treated and treatment-naive HIV patients.
The trial enrolled 775 patients who were taking other HIV medications in addition to Isentress. One subset received 800 milligrams of Isentress once-daily, another group received the standard 400-milligram dose twice per day.
After 48 weeks, HIV was lowered to undetectable levels in 83.2 percent of patients on the once-daily regimen and 88.9 percent of patients on the twice-daily schedule.
Source
http://www.reuters.com
Date of Publication
11/29/2010
Author
Ransdell Pierson
Article Type
General media
Article Category
Medical News
Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.
